Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Acetylcholinesterase (AChE) is an enzyme that rapidly catalyzes the breakdown of the neurotransmitter acetylcholine, thereby terminating synaptic signals. This hydrolysis is critical for precise neural communication, preventing overstimulation, and supporting functions like muscle contraction and cognitive processes.
Reported Benefits (Provisional)
Origin & History
Acetylcholinesterase (AChE) is a highly specific enzyme (EC 3.1.1.7) that catalyzes the rapid hydrolysis of the neurotransmitter acetylcholine into acetate and choline. Ubiquitously present at neuromuscular junctions, in the brain, and in red blood cells, it ensures precise termination of synaptic transmission at cholinergic synapses. This critical function is vital for accurate neural signaling, muscle control, and cognitive clarity.
Research Narrative (Provisional)
Acetylcholinesterase is thoroughly studied in neurobiology and pharmacotherapy, with extensive research on its role in synaptic transmission and cognitive function. Its activity is a well-established biomarker in neurodegenerative disease research and neurotoxicology. Inhibition of AChE is a key mechanism in current cognitive enhancement therapies, with ongoing investigations into gene polymorphisms and their links to cognitive resilience.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Catalyzes hydrolysis of acetylcholine into acetate and choline at synaptic clefts. - Requires no cofactors for its catalytic activity. - Choline product is recycled for new acetylcholine synthesis. - Functions with extremely high catalytic efficiency.
Reported Mechanism (Provisional)
Acetylcholinesterase (AChE) terminates neurotransmission by hydrolyzing acetylcholine into choline and acetate within the synaptic cleft. This occurs via a highly efficient Ser-His-Asp/Glu catalytic triad mechanism, where a serine residue initiates a nucleophilic attack on acetylcholine's ester bond. This rapid enzymatic action (approximately 5,000 acetylcholine molecules per second per AChE) ensures the swift cessation of cholinergic signals, allowing for precise control over muscle contraction and neural excitability.
Clinical Narrative (Provisional)
Extensive clinical and preclinical studies have elucidated Acetylcholinesterase's critical role in neurological function and disease. Research, including randomized controlled trials and observational studies, frequently uses AChE activity as a biomarker for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease, where diminished cholinergic signaling is implicated. Furthermore, competitive and non-competitive inhibitors of AChE are a cornerstone of pharmacotherapy for conditions such as Alzheimer's disease (e.g., donepezil, rivastigmine) and myasthenia gravis (e.g., pyridostigmine), demonstrating efficacy in improving cognitive symptoms or muscle strength, respectively. The therapeutic outcomes underscore AChE's importance as a drug target, with ongoing research exploring novel inhibitors for enhanced specificity and reduced side effects.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.